Table of Contents
In a study of 60 healthy adults, a single dose of psilocybin was associated with significantly reduced levels of the inflammatory markers TNF-alpha and IL-6 over the following week. Separate animal and cell-based studies suggest other psychedelics may also calm cytokine release, though the field is early and many questions remain.
- Inflammatory markers dropped after one dose: In a 60-person human study, psilocybin was linked to lower TNF-alpha and IL-6 levels for at least a week following a single administration.
- The anti-inflammatory effect may be separate from the psychedelic experience: Animal research comparing two structurally similar compounds found one reversed asthma-related inflammation completely while the other had no effect, suggesting the two properties can come apart.
- Ayahuasca reduced CRP in people with treatment-resistant depression: In one study, larger drops in the inflammatory marker CRP corresponded with greater mood improvements, hinting at a link between inflammation and mental health outcomes.
- Non-hallucinogenic derivatives are in early development: Compounds such as DLX-001 and DLX-159, described as psychedelic-informed but psychedelic-inactive, are being studied for antidepressant and anti-inflammatory effects without producing a psychedelic experience.
- Model
- Human (primary focus), animal, and in-vitro
- Sample
- 60 healthy participants in the psilocybin cytokine study; additional animal and cell models reviewed
- Dose
- Single dose of psilocybin (exact dose not specified in source)
- Design
- Review of multiple study designs; the psilocybin cytokine study measured TNF-alpha and IL-6 over one week post-dose
- Key outcome
- Significant reduction in TNF-alpha and IL-6 following one psilocybin dose; CRP reduction in ayahuasca recipients correlated with mood improvement
- Main limitation
- Small sample sizes, blinding difficulties inherent to psychedelic research, and the influence of prior drug experience complicate interpretation across studies
What the Research Examined
The primary source for this recap is a review article authored by Nicholas Barnes, Professor of Translational Pharmacology at the University of Birmingham, originally published in The Conversation and republished by ScienceAlert. The piece draws on a body of human, animal, and in-vitro research, including a study of 60 healthy participants that measured inflammatory cytokine levels before and after a single psilocybin dose. It also references an animal model of asthma comparing (R)-DOI and (R)-DOTFM, and human studies involving ayahuasca in both healthy volunteers and people with treatment-resistant depression.
The central question the review addresses is whether psychedelics act on the immune system through mechanisms that are distinct from those producing their perceptual effects. Scientists currently believe psychedelics act primarily on the 5-HT2A serotonin receptor, which triggers downstream chemical cascades. However, Barnes notes that the anti-inflammatory action may involve separate, less-characterized pathways, an idea supported by the divergent results seen with the two asthma-model compounds. This mechanistic separation, if confirmed, is the basis for developing what Barnes calls Pipi drugs: compounds that retain potential therapeutic benefits without the hallucinogenic profile. For readers wanting broader context on psilocybin research and its expanding mechanisms, that background is worth exploring alongside this immune-focused work.
Important caveats run throughout the review. Blinding is a structural challenge in psychedelic trials: participants who experience a full psychedelic effect cannot credibly be kept unaware of whether they received the active compound, which creates placebo-interpretation problems even for physiological outcomes like cytokine levels. Sample sizes across the reviewed studies are generally small, and variation in participants’ prior psychedelic experience adds another confounding layer. Barnes frames the evidence as promising but explicitly early-stage.
What the Findings Show
- TNF-alpha and IL-6 reduction.In a study of 60 healthy participants, a single psilocybin dose was associated with significantly lower levels of both TNF-alpha and IL-6 over the week following administration.
- CRP and mood correlation in ayahuasca study.In a study of healthy individuals and people with treatment-resistant depression, those given ayahuasca showed reduced CRP levels; the larger the CRP drop, the greater the improvement in mood scores.
- Divergent results in asthma animal model.In an animal model of asthma, (R)-DOI completely reversed inflammatory markers while the structurally similar (R)-DOTFM produced no anti-inflammatory effect, suggesting the anti-inflammatory and psychedelic properties are at least partially separable.
- Cell and animal cytokine blocking.In laboratory cell cultures and animal studies, DMT, LSD, and (R)-DOI were each observed to block cytokine release, molecules that drive conditions including rheumatoid arthritis, asthma, and depression-linked inflammation.
Taken together, the human cytokine data and the ayahuasca CRP findings point in a consistent direction: psychedelics appear capable of measurably altering inflammatory signaling in living people, not only in cell dishes or rodent lungs. The asthma-model compound comparison is particularly useful because it gives researchers a molecular foothold for separating desired anti-inflammatory action from the hallucinogenic mechanism, which is the conceptual foundation for the non-psychedelic derivative compounds now in early development. None of this is settled; the field is explicitly described as early-stage, and robust placebo-controlled trials in people with actual inflammatory disease have not yet been completed.
Can psilocybin lower inflammation markers in healthy people?
In one study of 60 healthy adults, a single psilocybin dose was linked to significantly reduced TNF-alpha and IL-6 levels over the following week. This is early human evidence, not a clinical finding in people with inflammatory disease, and the research field is still developing rigorous trial designs.
What This Is, and What It Is Not
This is This is a narrative review article summarizing a body of human, animal, and cell-based studies, written by an academic pharmacologist and published in The Conversation; it is not itself a controlled clinical trial.
This is not This review does not establish that psilocybin or any psychedelic treats or cures any inflammatory disease in humans, and no safe or effective dose has been established for immune modulation. Nothing here is medical advice; consult a qualified clinician before making any health decisions.
Our Take
Within our community, psilocybin has always been understood as something that acts on the whole person, not merely the brain. The emerging science around immune modulation offers a fascinating parallel: the sacrament may be doing quiet work at the cellular level, calming the body’s alarm systems even as it opens the mind. We hold that possibility with reverence and patience. The researchers themselves are careful, and we follow their lead. What is worth noting, spiritually, is that healing and wholeness have never been cleanly divided in the traditions that first worked with these medicines. That the science is now tracing lines between mood, inflammation, and consciousness feels less like a surprise and more like a confirmation of something indigenous knowledge-holders understood long before the lab did.
If this research stirs questions about your own relationship with inflammation, mental health, or the deeper work of integration, you are in the right place. The path toward understanding how these medicines interact with the body and spirit is long, and we walk it together here. Whether you are in a season of Grounding, gathering information before committing to a practice, or you are already deep in Integration, making sense of what has shifted inside you, the Mycelium Report is written for wherever you are standing. We are glad you are here.
Frequently Asked Questions
Does psilocybin reduce inflammation in humans?
One study of 60 healthy adults found that a single psilocybin dose significantly lowered TNF-alpha and IL-6 levels for about a week. This is early evidence and has not yet been replicated in people with inflammatory disease. The finding is promising but not conclusive.
How might psychedelics affect the immune system?
Research suggests psychedelics act on the 5-HT2A serotonin receptor and may block the release of inflammatory cytokines. Scientists believe the anti-inflammatory mechanism may be separate from the mechanism producing psychedelic experiences, though the exact pathways are not yet understood.
Are there psychedelic drugs being developed without the hallucinogenic effects?
Yes. Early-stage compounds such as DLX-001 and DLX-159, developed by Delix Therapeutics, are designed to produce antidepressant and anti-inflammatory effects without causing a psychedelic experience. These are still experimental and not approved for any use.
What is the main problem with doing clinical trials on psychedelics?
Blinding is extremely difficult. When a participant has a strong psychedelic experience, they know they did not receive a placebo, which makes it hard to separate the drug’s biological effects from expectation and placebo response, including for physical outcomes like inflammation markers.
What did ayahuasca studies show about inflammation and depression?
In one study including people with treatment-resistant depression, those who received ayahuasca showed reduced levels of the inflammatory marker CRP. Larger CRP reductions corresponded with greater mood improvements, suggesting inflammation may be one pathway connecting psychedelics to mental health benefits.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
